Evolution of MHC-based technologies used for detection of antigen-responsive T cells

Size: px
Start display at page:

Download "Evolution of MHC-based technologies used for detection of antigen-responsive T cells"

Transcription

1 Cancer Immunol Immunother (2017) 66: DOI /s FOCUSSED RESEARCH REVIEW Evolution of MHC-based technologies used for detection of antigen-responsive T cells Amalie Kai Bentzen 1 Sine Reker Hadrup 1 Received: 28 September 2016 / Accepted: 3 February 2017 / Published online: 17 March 2017 The Author(s) This article is an open access publication Abstract T cell-mediated recognition of peptide-major histocompatibility complex (pmhc) class I and II molecules is crucial for the control of intracellular pathogens and cancer, as well as for stimulation and maintenance of efficient cytotoxic responses. Such interactions may also play a role in the development of autoimmune diseases. Novel insights into this mechanism are crucial to understanding disease development and establishing new treatment strategies. MHC multimers have been used for detection of antigen-responsive T cells since the first report by Altman et al. showed that tetramerization of pmhc class I molecules provided sufficient stability to T cell receptor (TCR)-pMHC interactions, allowing detection of MHC multimer-binding T cells using flow cytometry. Since this breakthrough the scientific community has aimed for expanding the capacity of MHC multimer-based detection technologies to facilitate large-scale epitope discovery and immune monitoring in limited biological material. Screening of T cell specificity using large libraries of pmhc molecules is suitable for analyses of T cell recognition potentially at genome-wide levels rather than analyses restricted to a selection of model antigens. Such strategies provide novel insights into the immune specificities involved in This paper is a Focussed Research Review based on a presentation given at the Fourteenth Annual Meeting of the Association for Cancer Immunotherapy (CIMT), held in Mainz, Germany, 10th 12th May, It is part of a series of Focussed Research Reviews and meeting report in Cancer Immunology, Immunotherapy. * Sine Reker Hadrup sirha@vet.dtu.dk 1 Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark disease development and response to immunotherapy, and extend fundamental knowledge related to T cell recognition patterns and cross-recognition by TCRs. MHC multimerbased technologies have now evolved from detection of 1 2 different T cell specificities per cell sample, to include more than 1000 evaluable pmhc molecules using novel technologies. Here, we provide an overview of MHC multimer-based detection technologies developed over two decades, focusing primarily on MHC class I interactions. Keyword MHC multimer T cell receptor MHC class I Antigen specificity DNA barcode-labeled MHC multimers Abbreviations AG + Antigen positive CLIP Class II-associated invariant chain peptide CyTOF Cytometry by time-of-flight NACS Nucleic acid cell sorting p* UV-cleavable peptides pmhc Peptide-MHC SA Streptavidin Introduction Techniques for the detection of antigen-responsive T cells exploit the interaction between a given TCR and its pmhc recognition motif. T cell detection using multimerized pmhc molecules has evolved into the preferred method for detecting antigen-specific T cells. Over the past 20 years, since the first multimerizations of pmhc molecules [1], several approaches have aimed at matching the heterogeneity of T cells and epitope presentation to enhance our ability to map immune responses. The evolution of these Vol.:( )

2 658 Cancer Immunol Immunother (2017) 66: approaches, in terms of increasing complexity, is shown in Fig. 1. MHC multimer technologies have primarily been developed and applied for analyses of CD8 T cell responses, because MHC class I molecules have proven easier to handle in terms of protein folding and expression. Additionally, the MHC class I binding groove is more restricted in terms of the length of peptide bound hence, it is more straightforward to predict MHC class I binding peptides. Most of the technologies described in this review relate to detection of specific CD8 T cell responses, but they are in principle also applicable to MHC class II multimers and detection of CD4 T cell responses. Specific challenges associated with the production and use of MHC class II multimers are addressed in the final section. MHC molecules are largely unstable when they are not part of a complex with peptide. For this reason, pmhcbased technologies were initially restricted by the tedious production of pmhc molecules, where each peptide required an individual folding and purification procedure [2, 3]. Thus, the development of high-throughput strategies for T cell identification was constrained by the limiting step involving the generation of large libraries of pmhcs. A number of potential solutions to this challenge have been developed in the last decade. First, Schumacher et al. described the use of conditional MHC ligands that are cleaved upon exposure to 366 nm UV-light and can be exchanged with any MHC ligand of interest [4]. Using this strategy, individual MHC class I molecules are correctly refolded with carefully designed UV-cleavable peptides (p*), allowing sufficient stability of the complex. Individual p*mhc molecules are purified, and stored to serve as a source of stock molecules that can be exchanged with any ligand of interest upon exposure to UV-light. The UVcleavable conditional ligand-strategy has enabled the production of large numbers of different pmhc molecules in a high throughput manner [5, 6]. Today, such UV-ligands have been designed for a number of different MHC class I alleles, of both human and murine origin [7, 8]. An alternative strategy is the preferential folding of correctly oxidized MHC class I heavy chains. This allows efficient folding-reactions in small volumes, reduces the need for further optimization and can be used to create large libraries of diverse pmhc complexes [9]. More recently, it was discovered that certain di-peptides can assist folding and peptide exchange of MHC class I molecules [10, 11]. Dipeptides bind specifically to the F pocket of MHC class I molecules to facilitate peptide exchange and have so far Fig. 1 Evolution of MHC-based detection of antigen-responsive T cells. The methodologies are shown on a Log scale with increasing complexity in terms of the reported number of distinct antigenresponsive T cell populations that may by identified per sample. Most of the strategies offer the potential to screen for T cell reactivity at higher complexities. The listed sensitivities are based on screening for antigen-specific recognition among viable cells, though the mass cytometry and matrix-based approaches require a higher number of input cells. The DNA barcode-based methodology has been reported to have an increased sensitivity with an increased number of input cells. AG + antigen positive, CyTOF cytometry by time-of-flight

3 Cancer Immunol Immunother (2017) 66: been described and validated for peptide exchange in HLA- A*02:01, HLA-B*27:05, and H-2K b molecules. The dipeptide exchange technology has not yet been applied in larger T cell epitopes mapping strategies. Together, these technologies have enabled efficient production of large libraries of pmhc molecules, and consequently highthroughput detection of CD8 T cell recognition using pmhc-based reagents. Strategies for high throughput detection of antigen responsive T cells All the MHC-based strategies described throughout this report are summarized in Table 1. Detecting antigen responsive T cells using MHC microarrays Early attempts to improve the complexity of MHC multimer-based detection of antigen-responsive T cells were based on the success of gene-expression arrays, including the availability of efficient systems capable of quantifying fluorescent probes when spatially separated as spots on a microarray [12]. Protein-based microarrays have been developed [13] and the idea of a pmhc microarray allowing cell-capture based on specificity is appealing. Although several such systems have been developed [14 19], their application seems to be limited on account of a poor detection limit and low reproducibility compared to existing cytometry-based analyses. There is considerable overlap between MHC microarray approaches, where most work has focused on optimizing the supporting surface and modifying the conditions applied during binding and/or washing. In early studies by Soen et al. [14] and Chen et al. [16], microscope slides coated with polyacrylamide were selected as the optimal surface to lower cellular interaction while aiding protein binding. In these studies, the researchers were able to screen for seven different antigenspecificities in parallel and detect populations of T cells at a minimum frequency of 0.1% of total CD8 T cells [14] or, sensitivity may be enhanced up to tenfold when isolating CD8 T cells prior to loading them onto the microarray [16]. Using similar approaches, Stone et al. [15] and Brooks et al. [19] showed a considerable increase in complexity, screening for different antigen-responsive T cells in parallel, while also achieving a detection limit of approximately 0.1% of CD8 T cells. Using microarray approaches pmhc molecules can be co-spotted either with cytokine capture antibodies [16] or co-stimulatory molecules [15]. This may provide additional functional information to the T cell identification process. Moreover, the visualization of 659 activation markers once the T cells are captured at pmhc specific spots may improve the sensitivity of the assay [15, 16]. The study by Chen relied solely on T cell activation from multimeric pmhc:tcr interaction; however, multimeric pmhc:tcr interaction cannot be expected to activate all relevant T cells. Thus, counting on a lower detection limit due to the capture and visualization of activation markers would also increase the risk of missing those T cell populations that were not activated in such a system or misinterpreting their frequency. A general limitation with such array-based strategies is the propensity of a given T cell to pursue all potential pmhc interactions displayed on a given array. As a consequence, the frequency of antigen-responsive T cells in the cell preparations should be >0.1% to allow a robust readout. Deviren et al. [17] particularly addressed the issue of assay reproducibility and homogeneity, and by introducing a mild flow shear they obtained a more uniform distribution of captured T cells and a higher reproducibility. Consistent with the issue of ensuring cell interaction at all possible pmhc positions, they noted a greater variability associated with decreased surface area of each spotted pmhc. The nucleic acid cell sorting (NACS) approach developed by Kwong et al. [18] employed unique sequences of single-stranded DNA conjugated to distinct pmhc tetramers, which in turn were site-specifically assembled via hybridization onto glass slides printed with complementary DNA probes. This strategy offers an advantage over other MHC arrays in that T cells can be recovered from the glass slide by selective detachment using restriction enzymes. Detecting antigen responsive T cells using combinatorially labeled MHC multimers An alternative approach to pmhc microarrays is to utilize the increasing number of fluorescent labels available for flow cytometry. Two such parallel approaches were described in 2009, using combinatorial encoding of fluorescently labeled MHC multimers. Both of these approaches take advantage of the assumption that any given T cell in the cell samples will only bind one of the pmhc molecules in a given library. Thus, each distinct pmhc multimer can be assigned with a unique dual color code [20] or multivalent code [21], which is then used to identify the T cells binding to this particular pmhc molecule. When employing the unique dual color code, any T cell not matching the pre-determined color combinations is recorded as a background event. This provides a low limit of detection (0.002%) and a clear distinction between background events and specific pmhc binding with T cells. However, both approaches require that peptide sequences with minimal variation are analyzed in separate samples, to avoid cross-recognition between peptides within a given sample.

4 660 Cancer Immunol Immunother (2017) 66: Table 1 Summary of multiplex MHC-based strategies for detection of antigen-responsive T cells Strategy for high-throughput detection of specific CD8 T cell responses References Reported sensitivity (frequency of specific T cells) Reported order of complexity Combined with functional and/or phenotypic readout Offer recovery of AG specific T cells DNA barcode labeling of pmhc multimers Detection by sequencing Three-dimensional combinatorial encoding of metal labeled pmhc multimers Detection by cytometry by time-of-flight Two-dimensional combinatorial encoding of fluorescent labeled pmhc multimers Detection by flow cytometry Combinatorial pooling of fluorescent labeled pmhc multimers and splitting of sample material into each pool Detection by flow cytometry Multi-dimensional combinatorial encoding of fluorescent labeled pmhc multimers Detection by flow cytometry MHC microarray: pmhc tetramers spotted onto polyacrylamide slides combined with an aggressive washing scheme MHC microarray: DNA-probed pmhc tetramers spotted onto complementary DNA probe printed glass slide MHC microarray: Dimeric pmhcs spotted onto antibody-coated polyacrylamide microscopy slide MHC microarray: Dimeric pmhcs cospotted with cytokine capture antibodies onto polyacrylamide microscopy slide MHC microarray: pmhcs co-spotted onto polystyrene microscopy slide with cytokine capture antibodies and costimulatory molecules MHC microarray: pmhcs tetramers spotted onto polyacrylamide microscopy slide Bentzen et al. [28] 0.005% of CD8 + T cells 1031 different specificities per sample ( PBMCs) Newell et al. [25] 0.001% of CD8 + T cells (after MHC tetramer-based enrichment) Andersen et al. [31], Hadrup et al. [20] 109 different specificities per sample ( PBMCs) 0.002% of CD8 + T cells 36 different specificities per sample ( PBMCs) Yes Yes Yes No Yes Yes Klinger et al. [27] Not reported 16 different specificities per analysis a No a Yes Newell et al. [21] 0.01% of CD8 + T cells 15 different specificities per sample ( PBMCs) Brooks et al. [19] 0.02% of CD8 + T cells (after CD8 + T cell enrichment) 40 different specificities per assay ( T cells) Kwong et al. [18] 0.1% of CD8 + T cells 3 different specificities per assay (10 6 T cells) Deviren et al. [17] 0.01% of CD8 + T cells 2 different specificities per assay (10 6 cells) Chen et al. [16] 0.01% of CD8 + T cells 7 different specificities per assay (CD8 + T cells isolated from PBMCs) Stone et al. [15] 0.1% of CD8 + T cells 30 different specificities per assay (10 6 cells) Soen et al. [14] 0.1% of CD8 + T cells 7 different specificities per assay (10 6 cells) No Yes No No No Yes No No Yes No Yes No Yes (Ca 2+ levels) No a A non-mhc variation of this approach based on activation of T cells has been applied to screen for 30 specificities in parallel

5 Cancer Immunol Immunother (2017) 66: With the emergence of mass cytometry that uses heavy metal ions as tags, there has been a dramatic leap in the number of labels that can be applied in parallel [22 24]. Combining mass cytometry with combinatorial pmhc tetramer staining using a total of 10 metal labels applied in unique combinations of three labels per MHC multimer, Newell et al. were able to screen for 109 different antigen-specificities in one sample, while still leaving a substantial number of labels for parallel phenotype and functional analysis of T cells [25]. Despite the obvious progress made using this assay, there are a number of drawbacks associated with mass cytometry which may have impeded the widespread use of the method. This includes low cell recovery in the instrument (~30%), slow collection speed (~300 events/s), relatively low resolution, and high instrument and reagent cost [26]. Most importantly, the instrument offers no way of recovering distinct populations, as the cell structure is fully disrupted during the process. Thus, potential combination with genomic or transcriptomic sequencing-based approaches is not feasible. More recently, a matrix-based approach has been developed for T cell identification. In this method, a set of MHC multimers are split into matrix-defined pools, in such a way that no specific MHC multimer are present in all pools. The multimer pools are used to stain an equal number of cell aliquots derived from a given sample. The approach uniquely combines antigen recognition with sequencing of the TCRβ chain in that the MHC multimer positive and negative populations of each reagent pool are sorted and clonotypes enriched within the positive population are identified [27]. The advantage of this approach is that, theoretically, the number of antigen-responsive T cells that can be assessed in parallel increases exponentially with the number of pools created. In practice, 16 antigen-specificities have been analyzed in parallel (8 pools with 4 different MHC multimers per pool). The same study also uses an alternative, non-mhc-based approach that applies stimulation with different pools of peptides and sorting of the activated subset of T cells to screen for recognition of 30 peptide-antigens in parallel. This forms an attractive tool for detecting many antigen-responsive T cells simultaneously, especially since it also enables the identification of the corresponding TCRβ clonotypes. However, the necessity to split samples into a number of pools represents an inherent drawback in terms of detecting rare T cell populations especially in patient material that is often of limited access. Thus, until recently no technology has been available that simultaneously permits high-throughput analyses of T cells while tolerating the large diversity of T cell antigen specificity, thereby allowing detection of epitopes at potentially genome wide levels even in limited biological 661 samples, and recovery the positively interacting T cells for gene expression analysis. Next generation detection of antigen responsive T cells using DNA barcode labeled MHC multimers The most recent addition to the immunologist toolbox for detecting T cells based on antigen recognition involves implementation of a new type of label. Instead of using fluorescence or metal labels, as described in previous sections, we [28] have applied unique DNA barcodes that when attached to MHC multimers, form specific tags for the given pmhc epitopes. DNA barcodes can be designed with a complexity of up to different sequences, each forming a unique tag [29]. As a result, this strategy is not limited by the number of available labels, which has previously been the most critical barrier to high-throughput detection of antigen-responsive T cells. We have shown that this approach can be applied to screen for more than 1000 specificities in a single sample. These MHC multimers are generated on a backbone of polysaccharide dextran that carries a number of free streptavidin (SA) binding sites. These SA binding-sites are used to co-attach biotinylated molecules, recombinant pmhcs, and DNA barcodes (Fig. 2). In this manner, every pmhc epitope is associated with a unique DNA barcode (e.g., barcode#1 codes for pmhc#1, barcode#2 codes for pmhc#2 and so on) that can be easily recovered by high-throughput sequencing. Moreover, all MHC multimers are conjugated to the same fluorochrome (PE), whose signal-intensity serves as a means to collectively sort any T cells that associate with the MHC multimers. Thus, first the T cells are incubated with large collections (>1000) of DNA barcode-labeled MHC multimers and all multimer positive cells are sorted, and then the associated DNA barcodes are amplified and the unique sequences revealed after sequencing (Fig. 2). Ultimately, the number of reads for a specific DNA barcode matching the corresponding pmhc correlates with the presence of antigen-responsive T cells within the sorted population. In contrast to both single MHC multimer staining and combinatorial encoding of MHC multimers (using either fluorescence or metal labels) where the signal intensities are applied directly to define the antigen recognition of a given T cell population, the antigen-responsiveness determined using DNA barcode-labeled MHC multimers are defined in a retrospective analysis of sequence reads, providing an estimate for the number of antigen-responsive T cells rather than the exact number. Unique molecular identifiers [30] are incorporated in the DNA barcode design to provide a means of accounting for amplification bias, and thus the number of sequence reads reflects the number of

6 662 Cancer Immunol Immunother (2017) 66: specific pmhc:tcr interactions in the population as a whole. In other words, when calculating the frequency of antigen-responsive T cells based on the number of barcode reads and the frequency of total multimer-positive cells, the determined frequencies are based on an average number of pmhc:tcr interactions for all T cells in the potentially heterogeneous population. This strategy may introduce a bias in frequency determination, depending on pmhc:tcr affinity and TCR expression level on the given cell population. Practically, this phenomenon seems to provide limited variability to the DNA barcode-based determination of T cell frequencies, resulting in a very tight correlation with T cell frequencies determined by combinatorially encoded fluorescently labeled MHC multimers [r 2 = 0.967, across 10 healthy donors (32 responses) and r 2 = across 11 melanoma patients (15 responses)] [28]. The DNA barcode-based approach offers the advantage that it is less dependent on stringent fluorescent-based separation of multimer-positive from multimer-negative events, because even events that may not be fluorescently separated due to low level pmhc multimer interactions will still bind enough DNA barcode-labeled MHC multimers to allow recovery of their specific DNA barcode element, thus enabling the identification of the TCR specificity. The technology therefore represents an attractive tool for detecting low avidity TCR:pMHC interactions such as shared tumor-associated antigens. When applying cytometry-based approaches, the signal intensity associated with a given pmhc is the only measure distinguishing those T cells that interact specifically with MHC multimers and those that do not. Therefore, it is essential that a given T cell binds numerous MHC multimers, to obtain sufficient fluorescence intensity and thereby enable unambiguous identification of their specificity. A T cell that has low affinity TCR:pMHC interactions or low surface TCR expression may not bind sufficient MHC multimers to obtain fluorescent separation, but will still provide a signal from the attached DNA barcode. We have demonstrated that the antigen-responsive composition of T cells in a sample can be determined independent of any fluorescent label, by sorting the whole CD8 T cell population as opposed to only the multimer-positive T cells [28]. In line with the reasoning that antigen recognition can be determined from the number of DNA barcode reads irrespective of the fluorescent-based separation of multimer-positive cells, other criteria can be applied to determine which cell populations to sort. Throughout the workflow of the DNA barcode-based strategy only a few different fluorescent labels are applied to determine the viable CD8 positive population, leaving a considerable number of fluorescent labels to stain for other cell properties. Thus, one can distinguish between CD8 T cells with certain phenotypic characteristics or of a certain activation status, Fig. 2 Detection of antigen-responsive T cells using the DNA barcode-labeled MHC multimer methodology. A PE-labeled dextran backbone carrying a number of SA binding sites (illustrated as an X) is applied to co-attach biotinylated molecules; DNA barcodes and pmhcs. Thus >1000 pmhc multimers can be generated, each carrying a different DNA barcode. All MHC multimer binding T cells are sorted based on the common fluorescent label and the associated DNA barcodes are amplified and sequenced. The relative numbers of DNA barcode reads are used to determine the composition of antigen-responsive T cells in the sample and retrospectively determine the composition of antigenresponsive T cells among the different populations through sequencing of the associated DNA barcodes. This strategy was illustrated with the activation of antigen-responsive T cells present in healthy donor blood or tumor-infiltrating lymphocytes (TILs), through stimulation with a pool of common virus-derived peptides or autologous tumor cell line, respectively. Subsequently, samples are stained with collections of DNA barcode-labeled MHC multimers and intracellular activation markers. The fluorescent signal from the MHC multimers was disregarded and cells were sorted exclusively based on the cytokine secretion profile [28]. Thus, we have shown that DNA barcodes associated

7 Cancer Immunol Immunother (2017) 66: with pmhc multimers recognized by T cells that have been exposed to their target antigen, can completely or predominantly be recovered from the activated subset of CD8 T cells. On the other hand, the DNA barcodes associated with epitopes not available for T cells during stimulation are only found in the non-activated subset of CD8 T cells. TCR downregulation following T cell activation has previously conflicted with effective combinations of MHC multimer staining and T cell activation for low-avidity T cells; however, the DNA barcode-labeled strategy seems to be less sensitive to such phenomena, because even low levels of pmhc multimer interactions (insufficient for fluorescent separation) will retain a DNA barcode signal, as described above [28]. Inarguably, the greatest advantage of using DNA barcode-labeled MHC multimers is the possibility to screen in an unbiased manner for T cell reactivity across large libraries of pmhc epitopes in a single sample. Applying the current DNA barcode design, we can generate unique labels in the order of ; thus the technology has the potential for analyzing T cell reactivity at close to genome-wide levels. Using earlier high-throughput methodologies it has not been possible to analyze for T cell reactivity of structurally related pmhc epitopes in the same sample, e.g., peptides differing only at a single amino-acid position or 9-, 10- or 11-mer versions of the same peptide with a given HLA restriction. However, this issue could be circumvented without much difficulty since these strategies, being only semi-high-throughput, have often required the splitting of samples into several tubes to analyze all potential epitopes of interest. Users simply have to ensure that different versions of a pmhc epitope were represented in different MHC reagent mixtures. However, with the possibility of screening, e.g., a full cancer-mutagenome in one sample, it is essential that structurally related pmhc epitopes can be identified in parallel using only one mixture of MHC reagents. The DNA barcode-based approach provides information on recognition of a given pmhc molecule, but such recognition may likely be shared among several T cell populations. Thus, cross reactivity to multiple epitopes in a given library will not disrupt analyses. Analyzing the crossreactive features and relative recognition profile among different pmhc complexes can be accomplished when T cells are assessed at a single cell level. The DNA barcode labeling of MHC multimers provides a new tool to gain insight to T cell recognition in complex disease situations. Nonetheless, the main disadvantage of the methodology is that it merely provides an estimate for T cell frequencies, and does not offer any possibility for direct visual assessment of the findings in terms of T cell recognition. Thus, users rely on good quality assurance of the sequencing procedure and validated programs to translate read number into the presence of antigen-responsive 663 T cells. Furthermore, pmhc binding T cells are lysed in the process of DNA barcode amplification, and are consequently not available for subsequent cell culturing. Novel insights into T cell recognition of cancer Due to the limited number of cells available directly from excised tumor fragments, it has for most prior purposes been necessary to expand TILs in vitro to enable analyses of antigen recognition of the relevant pmhc multimer molecules. Previous studies have shown that expansion of T cells may introduce a bias in antigen recognition due to variable growth potential of TILs, and specifically, preferential growth of T cell populations that recognize virus epitopes [31]. Application of large-scale screening strategies reduces the need for such in vitro expansion of T cells, and allows for T cell recognition analyses on broad spectra of pmhc epitopes even in minute amounts of patient material. We have shown the possibility for detection of antigen-responsive T cells towards a large shared melanoma library (composed of 175 DNA-barcoded MHC multimers) in tumor digest from melanoma patients without the need for T cell expansion [25]. Moreover, because of the amount of data that can be recovered from a relatively small sized sample, the DNA barcode-based methodology represents an attractive tool to analyze patient samples taken at multiple time-points, to follow the dynamics of an immune response and the response to certain treatments. Since it is no longer necessary to split samples into multiple aliquots to screen for antigen recognition, it is possible to look for T cell recognition in an unbiased fashion in samples with a considerably greater number of precursor cells than what had previously been applied. With increasing cell numbers, the stochastic variation of the compositions of antigen-specific T cell populations is reduced, and the chance for detecting low-frequent T cell populations increases, reflecting a higher absolute number of pmhc responsive T cells in the given sample. The advantages of being able to include more T cells in the initial binding reaction were illustrated in a study where we screened for T cell recognition of predicted HLA-binding peptide sequences containing cancer-specific mutations in two patients with non-small cell lung carcinoma. A large number of personal neoepitope peptides had been predicted for each patient resulting in libraries of 288 and 417 different pmhcs, respectively [32]. In these patients, T cell recognition was assessed from analyzing in vitro expanded TILs from one or more regions of lung tissue. A total of one neoepitope-responsive T cell population was detected using combinatorial encoding of fluorescent labels, which allowed the inclusion of only TILs/ MHC reaction mixture (9 13 different reaction mixtures/

8 664 Cancer Immunol Immunother (2017) 66: patient specific neoepitope library). Despite the limited availability of sample, we were able to detect a total of nine different neoepitope-responsive T cells when applying the DNA barcode-based MHC multimer technology. This may partly be explained by the greater number of cells included in the initial binding reactions ( TILs in one MHC reaction mixture) and due to the possibility for analyzing peripheral blood. In fact, several of the detected responses were predominantly or exclusively found in the peripheral blood sample [28]. MHC class II multimers for detection of antigen responsive CD4 T cells An additional challenge in the field of immune analyses relates to the characterization of antigen-responsive CD4 T cells. Antigen-responsive CD4 T cells are believed to play a significant role in tumor-cell recognition [33, 34] and development of autoimmune diseases [35, 36]. Detection of antigen-specific CD4 T cells using MHC II multimers is feasible [37], but high-throughput detection strategies are still challenging. MHC class II molecules require, for most alleles, expression in mammalian cells [38], although more recent strategies has proven that functional HLA- DR molecules can be expressed and refolded from E. coli [39]. Peptide exchange can be facilitated using constructs that includes a thrombin cleavage site next to a class IIassociated invariant chain peptide (CLIP). MHC II are produced with CLIP embedded in the peptide binding groove, but following thrombin-based cleavage of the linker, CLIP can be displaced by simple competition with ligands of interest. This strategy has been exploited to generate small libraries of MHC II molecules, DRB1*0101, DRB1*0401, DRB5*0101 and DRB1*1501 [40]. Importantly, it is much more difficult to predict which peptides will form stable complexes with MHC class II compared to class I since the open structure of the MHC II molecule enables peptide fragments to protrude from the binding groove and thus allows much more variable side chains of cargo peptides [41]. Moreover, it is presumed that CD4 TCRs bind with lower affinity to their cognate pmhc epitope than CD8 TCRs [42]. This may be a particularly important limitation in the ability to detect self-antigen and tumor-specific CD4 + T cell populations. Along with the improvements in prediction tools for MHC-II ligands [43] and the development of efficient peptide replacement systems for generating large libraries of MHC class II monomers [40], the technologies for largescale detection of antigen-responsive CD8 T cells described herein should also be feasible for detection of CD4 T cells. Specifically, the DNA barcode-based methodology may provide an advantage, compared to the other methods, for detection of CD4 T cells using MHC II multimers, due to its particular advantages in terms of detecting T cells with low-affinity TCR:pMHC interactions, that are not well separated based on fluorescence labeling alone. However, the use of DNA barcode labeled MHC II multimers has not yet been investigated. Future implications At present proof-of-principle have been provided that up to 1031 DNA barcode-labeled MHC multimers can be applied in one reaction mixture to detect several populations of antigen-responsive T cells in parallel. This complexity, though already representing a tenfold leap compared to earlier methodologies, can potentially be increased to >10, ,000 differently labeled MHC multimers. Since the potential complexity of the DNA barcode label is in the order of 10 10, the limitations inherent to combinatorial encoding using fluorescent or metal tags have been removed. However, new bottlenecks may arise with increasing library sizes. Moving the complexity of MHC multimer libraries within the range of 10, ,000 specificities will require automation of all aspects of the pmhc multimer production as well as more efficient and cost-effective production of synthetic peptides. Furthermore, it will most likely require the development of microfluidics systems that can ensure efficient pmhc interaction with all T cells in a given sample. In the era of personalized medicine and with accumulating types of immunotherapeutic strategies being employed, it is becoming increasingly important to understand the T cell-mediated recognition of cancer cells, and identify biomarkers predicting the response to therapy potentially based on experimental analyses of T cell recognition (Fig. 3). Recent data suggest that a substantial fraction of the T cell reactivity induced during checkpoint inhibition is directed towards neoepitopes that are generated through genetic alterations [44 46]. However, current tools for neoepitope prediction are imprecise and identification of tumor-rejection epitopes at genome-wide levels requires large-scale analyses of T cell reactivity. The recently developed technology based on DNA barcode-labeled MHC multimers has the potential to improve such T cell analyses, and importantly, enables detection of T cells in both peripheral blood and tissue biopsies [28]. Furthermore, increasing knowledge of the T cell recognition profile in cancer patients can be used to improve prediction tools for cancer-specific neoepitopes, and help in identifying the impact of genetic heterogeneity in T cell recognition [32].

9 Cancer Immunol Immunother (2017) 66: Fig. 3 Detection of neoepitoperesponsive T cells in cancer patients. T cell responses in cancer patients rely to a large extent on epitope recognition defined by both expression and mutational patterns given in the individual patient s tumor. Targeting of mutation-derived neoepitopes in cancer therapy requires the identification of personalized epitope maps and prediction or preferably testing for immunogenicity. Highthroughput strategies for T cell analyses will play an important role in this process Acknowledgements The work was funded by the Danish Cancer Society (ID: R72-A S2), the Lundbeck Foundation Fellowship (ID: R ), and the Danish Research Council (FSS- ID: and DFF-ID: ). Compliance with ethical standards Conflict of interest The DNA barcode-labeled MHC multimer technology is patented (WO and WO ) by the authors, the Capital Region of Copenhagen, University Hospital Herlev and Immudex. The technology is licensed to Immudex. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. References 1. Altman JD, Moss PA, Goulder PJ et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: doi: /science Bakker AH, Schumacher TNM (2005) MHC multimer technology: current status and future prospects. Curr Opin Immunol 17: doi: /j.coi Garboczi DN, Hung DT, Wiley DC (1992) HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 89: Toebes M, Coccoris M, Bins A et al (2006) Design and use of conditional MHC class I ligands. Nat Med 12: doi: /nm Bakker AH, Hoppes R, Linnemann C et al (2008) Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci USA 105: doi: / pnas Rodenko B, Toebes M, Hadrup SR et al (2006) Generation of peptide-mhc class I complexes through UV-mediated ligand exchange. Nat Protoc 1: doi: / nprot Frøsig TM, Yap J, Seremet T et al (2015) Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05. Cytom Part A 87: doi: /cyto.a Chang CXL, Tan AT, Or MY et al (2013) Conditional ligands for Asian HLA variants facilitate the definition of CD8 + T-cell responses in acute and chronic viral diseases. Eur J Immunol 43: doi: /eji Leisner C, Loeth N, Lamberth K et al (2008) One-pot, mix-andread peptide-mhc tetramers. PLoS One 3:e1678. doi: / journal.pone Saini SK, Ostermeir K, Ramnarayan VR et al (2013) Dipeptides promote folding and peptide binding of MHC class I molecules. Proc Natl Acad Sci USA 110: doi: / pnas

10 666 Cancer Immunol Immunother (2017) 66: Saini SK, Schuster H, Ramnarayan VR et al (2015) Dipeptides catalyze rapid peptide exchange on MHC class I molecules. Proc Natl Acad Sci USA 112: doi: /pnas Schena M, Shalon D, Davis RW, Brown PO (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: MacBeath G, Schreiber SL (2000) Printing proteins as microarrays for high-throughput function determination. Science 289: Soen Y, Chen DS, Kraft DL et al (2003) Detection and characterization of cellular immune responses using peptide- MHC microarrays. PLoS Biol 1:E65. doi: /journal. pbio Stone JD, Demkowicz WE, Stern LJ (2005) HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. Proc Natl Acad Sci USA 102: doi: / pnas Chen DS, Soen Y, Stuge TB et al (2005) Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2:e265. doi: /journal.pmed Deviren G, Gupta K, Paulaitis ME, Schneck JP (2007) Detection of antigen-specific T cells on p/mhc microarrays. J Mol Recognit 20: doi: /jmr Kwong GA, Radu CG, Hwang K et al (2009) Modular nucleic acid assembled p/mhc microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 131: doi: /ja Brooks SE, Bonney SA, Lee C et al (2015) Application of the pmhc array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. PLoS One 10:e doi: /journal.pone Hadrup SR, Bakker AH, Shu CJ et al (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. doi: /nmeth Newell EW, Klein LO, Yu W, Davis MM (2009) Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 6: doi: / nmeth Ornatsky OI, Baranov VI, Bandura DR et al (2006) Messenger RNA detection in leukemia cell lines by novel metal-tagged in situ hybridization using inductively coupled plasma mass spectrometry. Transl Oncogenomics 1: Bandura DR, Baranov VI, Ornatsky OI et al (2009) Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 81: doi: /ac901049w 24. Bendall SC, Simonds EF, Qiu P et al (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332: doi: /science Newell EW, Sigal N, Nair N et al (2013) Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol. doi: / nbt Spitzer MH, Nolan GP (2016) Mass cytometry: single cells, many features. Cell 165: doi: /j.cell Klinger M, Pepin F, Wilkins J et al (2015) Multiplex identification of antigen-specific T Cell receptors using a combination of immune assays and immune receptor sequencing. PLoS One 10:e doi: /journal.pone Bentzen AK, Marquard AM, Lyngaa R et al (2016) Large-scale detection of antigen-specific T cells using peptide-mhc-i multimers labeled with DNA barcodes. Nat Biotechnol 34: doi: /nbt Xu Q, Schlabach MR, Hannon GJ, Elledge SJ (2009) Design of 240,000 orthogonal 25mer DNA barcode probes. Proc Natl Acad Sci USA 106: doi: /pnas Kivioja T, Vähärautio A, Karlsson K et al (2011) Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods 9: doi: /nmeth Andersen RS, Thrue CA, Junker N et al (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72: doi: / can McGranahan N, Furness AJS, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351: doi: /science.aaf Linnemann C, van Buuren MM, Bies L et al (2015) Highthroughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. Nat Med 21: doi: /nm Kreiter S, Vormehr M, van de Roemer N et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: doi: /nature Roep BO, Peakman M (2011) Diabetogenic T lymphocytes in human type 1 diabetes. Curr Opin Immunol 23: doi: /j.coi Hohlfeld R, Dornmair K, Meinl E, Wekerle H (2015) The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4 + T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol 15: doi: / S (15) Crawford F, Kozono H, White J et al (1998) Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8: Vollers SS, Stern LJ (2008) Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123: doi: /j x 39. Braendstrup P, Justesen S, Osterbye T et al (2013) MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides. PLoS One 8:e doi: /journal.pone Day CL, Seth NP, Lucas M et al (2003) Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Investig 112: doi: /jci Rudensky AYu, Preston-Hurlburt P, Hong SC et al (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353: doi: /353622a0 42. Cole DK, Pumphrey NJ, Boulter JM et al (2007) Human TCRbinding affinity is governed by MHC class restriction. J Immunol 178: doi: /jimmunol Andreatta M, Karosiene E, Rasmussen M et al (2015) Accurate pan-specific prediction of peptide-mhc class II binding affinity with improved binding core identification. Immunogenetics 67: doi: /s y 44. Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371: doi: /nejmoa Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: doi: /science.aaa Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and Transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell 165: doi: /j.cell

Our T cell epitope test service offers you:

Our T cell epitope test service offers you: Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made

More information

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints Supplementary Figure 1 Using DNA barcode-labeled MHC multimers to generate TCR fingerprints (a) Schematic overview of the workflow behind a TCR fingerprint. Each peptide position of the original peptide

More information

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed

More information

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in

Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL

More information

Nature Biotechnology: doi: /nbt Supplementary Figure 1. Binding capacity of DNA-barcoded MHC multimers and recovery of antigen specificity

Nature Biotechnology: doi: /nbt Supplementary Figure 1. Binding capacity of DNA-barcoded MHC multimers and recovery of antigen specificity Supplementary Figure 1 Binding capacity of DNA-barcoded MHC multimers and recovery of antigen specificity (a, b) Fluorescent-based determination of the binding capacity of DNA-barcoded MHC multimers (+barcode)

More information

10/3/2016. Immunotherapy of human cancer can be highly effective: TIL therapy. What T cells See on Human Cancer. Anti-PD-1. Anti-PD-1 and anti-ctla-4

10/3/2016. Immunotherapy of human cancer can be highly effective: TIL therapy. What T cells See on Human Cancer. Anti-PD-1. Anti-PD-1 and anti-ctla-4 Immunotherapy of human cancer can be highly effective: TIL therapy Tumor-infiltrating lymphocytes (TIL) are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 What T cells See on Human Cancer

More information

Dissecting therapy-induced T-cell responses in melanoma

Dissecting therapy-induced T-cell responses in melanoma Dissecting therapy-induced T-cell responses in melanoma Tumor-infiltrating lymphocyte (TIL) therapy of melanoma TIL are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 Patient pretreated

More information

Mass Cytometry Applications for Immunology Research. Pub Note PN 13 01_150505

Mass Cytometry Applications for Immunology Research. Pub Note PN 13 01_150505 Mass Cytometry Applications for Immunology Research Pub Note PN 13 01_150505 Contents Continuum of CD8 + T cell phenotypes revealed by deep profiling with mass cytometry 3 The transcriptional landscape

More information

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,

More information

Mass Cytometry Publication List

Mass Cytometry Publication List Mass Cytometry Publication List 2014 Publications 1 Becher, B., et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol 15 (12): 1181-1189, 2014. Behbehani, G.K., et al. Transient

More information

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate

More information

Chapter 7 Conclusions

Chapter 7 Conclusions VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy

More information

Neo-antigen recognition as a major ingredient in clinically effective cancer immunotherapies

Neo-antigen recognition as a major ingredient in clinically effective cancer immunotherapies Neo-antigen recognition as a major ingredient in clinically effective cancer immunotherapies WIN, 06-2015 Evidence & Implications Ton Schumacher I have the following financial relationships to disclose:

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Use of BONSAI decision trees for the identification of potential MHC Class I peptide epitope motifs.

Use of BONSAI decision trees for the identification of potential MHC Class I peptide epitope motifs. Use of BONSAI decision trees for the identification of potential MHC Class I peptide epitope motifs. C.J. SAVOIE, N. KAMIKAWAJI, T. SASAZUKI Dept. of Genetics, Medical Institute of Bioregulation, Kyushu

More information

MHC class I MHC class II Structure of MHC antigens:

MHC class I MHC class II Structure of MHC antigens: MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain

More information

Immune surveillance: The immune system can recognize and destroy nascent malignant cells

Immune surveillance: The immune system can recognize and destroy nascent malignant cells Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor

More information

DIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE

DIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE DIRECT IDENTIFICATION OF NEO-EPITOPES IN TUMOR TISSUE Eustache Paramithiotis PhD Vice President, Biomarker Discovery & Diagnostics 17 March 2016 PEPTIDE PRESENTATION BY MHC MHC I Antigen presentation by

More information

AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification

AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification BD AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification Overview of BD AbSeq antibody-oligonucleotide conjugates. High-throughput

More information

New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine

New technologies for studying human immunity. Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine New technologies for studying human immunity Lisa Wagar Postdoctoral fellow, Mark Davis lab Stanford University School of Medicine New strategies: Human immunology is ideal for a systems approach We have

More information

Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms

Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Wendy Broom, Ph.D. Keystone: Translational Systems Immunology, Snowbird February 1st 2018

More information

Emerging Tissue and Serum Markers

Emerging Tissue and Serum Markers Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice

More information

Personalized Cancer Neoantigen Vaccines

Personalized Cancer Neoantigen Vaccines Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,

More information

Supplementary Information

Supplementary Information Supplementary Information High throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T-cells in human melanoma Carsten Linnemann, Marit M. van Buuren, Laura Bies, Els M.E.Verdegaal,

More information

Machine Learning For Personalized Cancer Vaccines. Alex Rubinsteyn February 9th, 2018 Data Science Salon Miami

Machine Learning For Personalized Cancer Vaccines. Alex Rubinsteyn February 9th, 2018 Data Science Salon Miami Machine Learning For Personalized Cancer Vaccines Alex Rubinsteyn February 9th, 2018 Data Science Salon Miami OpenVax @ Mount Sinai Focus: personalized cancer vaccines Machine learning for immunology Cancer

More information

Immunology - Lecture 2 Adaptive Immune System 1

Immunology - Lecture 2 Adaptive Immune System 1 Immunology - Lecture 2 Adaptive Immune System 1 Book chapters: Molecules of the Adaptive Immunity 6 Adaptive Cells and Organs 7 Generation of Immune Diversity Lymphocyte Antigen Receptors - 8 CD markers

More information

Major Histocompatibility Complex (MHC) and T Cell Receptors

Major Histocompatibility Complex (MHC) and T Cell Receptors Major Histocompatibility Complex (MHC) and T Cell Receptors Historical Background Genes in the MHC were first identified as being important genes in rejection of transplanted tissues Genes within the MHC

More information

EBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham

EBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205 AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information

An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution

An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution James H. Godsey, Ph.D. Vice President, Research & Development Clinical Sequencing Division (CSD) Life

More information

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Welcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/39812 holds various files of this Leiden University dissertation Author: Buuren, Marit M. van Title: Analysis of the neo-antigen specific T cell response

More information

Antigen Recognition by T cells

Antigen Recognition by T cells Antigen Recognition by T cells TCR only recognize foreign Ags displayed on cell surface These Ags can derive from pathogens, which replicate within cells or from pathogens or their products that cells

More information

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org

More information

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the

More information

MHC MULTIMER PROFICIENCY PANEL 2017

MHC MULTIMER PROFICIENCY PANEL 2017 MHC MULTIMER PROFICIENCY PANEL 2017 August 2017 CONTACT Charlotte Halgreen ProficiencyPanel@immudex.com FOR MORE INFORMATION www.proficiencypanel.com MHC MULTIMER PROFICIENCY PANEL 2017 This report summarizes

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Principles of Adaptive Immunity

Principles of Adaptive Immunity Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors

More information

Third line of Defense

Third line of Defense Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)

More information

The Major Histocompatibility Complex (MHC)

The Major Histocompatibility Complex (MHC) The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens

More information

The PD-1 pathway of T cell exhaustion

The PD-1 pathway of T cell exhaustion The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1

More information

MHC MULTIMER PROFICIENCY PANEL 2015

MHC MULTIMER PROFICIENCY PANEL 2015 MHC MULTIMER PROFICIENCY PANEL 2015 July 2015 CONTACT Charlotte Halgreen ProficiencyPanel@immudex.com FOR MORE INFORMATION www.proficiencypanel.com MHC MULTIMER PROFICIENCY PANEL 2015 This report summarizes

More information

Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire

Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Geoffrey M. Lowman, PhD Senior Staff Scientist EACR - 02 July 2018 For Research Use Only. Not for use in diagnostic

More information

Antigen Receptor Structures October 14, Ram Savan

Antigen Receptor Structures October 14, Ram Savan Antigen Receptor Structures October 14, 2016 Ram Savan savanram@uw.edu 441 Lecture #8 Slide 1 of 28 Three lectures on antigen receptors Part 1 (Today): Structural features of the BCR and TCR Janeway Chapter

More information

Introduction to Immunology Part 2 September 30, Dan Stetson

Introduction to Immunology Part 2 September 30, Dan Stetson Introduction to Immunology Part 2 September 30, 2016 Dan Stetson stetson@uw.edu 441 Lecture #2 Slide 1 of 26 CLASS ANNOUNCEMENT PLEASE NO TREE NUTS IN CLASS!!! (Peanuts, walnuts, almonds, cashews, etc)

More information

T cell recognition. Statistics & Dynamics of Functional Sensitivity

T cell recognition. Statistics & Dynamics of Functional Sensitivity T cell recognition Statistics & Dynamics of Functional Sensitivity C Molina-París LEEDS APPLIED MATHEMATICS G Lythe LEEDS APPLIED MATHEMATICS A K Sewell CARDIFF MEDICAL BIOCHEMISTRY & IMMUNOLOGY L Wooldridge

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM. !! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)

More information

Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI

Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of

More information

DISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding

DISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this

More information

Antigen Presentation to T lymphocytes

Antigen Presentation to T lymphocytes Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antigen processing: How are

More information

Current practice, needs and future directions in immuno-oncology research testing

Current practice, needs and future directions in immuno-oncology research testing Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Third line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!

Third line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization! Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow

More information

A HLA-DRB supertype chart with potential overlapping peptide binding function

A HLA-DRB supertype chart with potential overlapping peptide binding function A HLA-DRB supertype chart with potential overlapping peptide binding function Arumugam Mohanapriya 1,2, Satish Nandagond 1, Paul Shapshak 3, Uma Kangueane 1, Pandjassarame Kangueane 1, 2 * 1 Biomedical

More information

DEVELOPMENT OF CELLULAR IMMUNOLOGY

DEVELOPMENT OF CELLULAR IMMUNOLOGY DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer

More information

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice

More information

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant

More information

Lecture 6. Burr BIO 4353/6345 HIV/AIDS. Tetramer staining of T cells (CTL s) Andrew McMichael seminar: Background

Lecture 6. Burr BIO 4353/6345 HIV/AIDS. Tetramer staining of T cells (CTL s) Andrew McMichael seminar: Background Lecture 6 Burr BIO 4353/6345 HIV/AIDS Andrew McMichael seminar: Background Tetramer staining of T cells (CTL s) 1. Vβ 19: There are 52 T cell receptor (TCR) Vβ gene segments in germ line DNA (See following

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint

Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint APPLICATION NOTE AlphaLISA Technology Authors: Matthew Marunde Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint Introduction

More information

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

Adaptive Immune System

Adaptive Immune System Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,

More information

Surface plasmon resonance (SPR) analysis

Surface plasmon resonance (SPR) analysis Surface plasmon resonance (SPR) analysis Soluble CD8αα and was manufactured as described previously. 1,2 The C12C heterodimeric TCR was produced using an engineered disulfide bridge between the constant

More information

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry

Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Nat Met, April 2014 Nat Med, April 2014 Next-Generation Immunohistochemistry: Multiplex tissue imaging with mass cytometry Journal Club Timo Böge Overview Introduction Conventional Immunohistochemistry

More information

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells 1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:

More information

Principle of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte.

Principle of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte. FluoroSpot 1 The principle objective of the FluoroSpot assay is the simultaneous measurement of dual cytokine secretion at the single cell level. This is accomplished by using a mixture of monoclonal antibodies

More information

Transcript-indexed ATAC-seq for immune profiling

Transcript-indexed ATAC-seq for immune profiling Transcript-indexed ATAC-seq for immune profiling Technical Journal Club 22 nd of May 2018 Christina Müller Nature Methods, Vol.10 No.12, 2013 Nature Biotechnology, Vol.32 No.7, 2014 Nature Medicine, Vol.24,

More information

I. Critical Vocabulary

I. Critical Vocabulary I. Critical Vocabulary A. Immune System: a set of glands, tissues, cells, and dissolved proteins that combine to defend against non-self entities B. Antigen: any non-self chemical that triggers an immune

More information

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels

More information

ANALYTISCHE STRATEGIE Tissue Imaging. Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich

ANALYTISCHE STRATEGIE Tissue Imaging. Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich ANALYTISCHE STRATEGIE Tissue Imaging Bernd Bodenmiller Institute of Molecular Life Sciences University of Zurich Quantitative Breast single cancer cell analysis Switzerland Brain Breast Lung Colon-rectum

More information

Key Concept B F. How do peptides get loaded onto the proper kind of MHC molecule?

Key Concept B F. How do peptides get loaded onto the proper kind of MHC molecule? Location of MHC class I pockets termed B and F that bind P and P9 amino acid side chains of the peptide Different MHC alleles confer different functional properties on the adaptive immune system by specifying

More information

B F. Location of MHC class I pockets termed B and F that bind P2 and P9 amino acid side chains of the peptide

B F. Location of MHC class I pockets termed B and F that bind P2 and P9 amino acid side chains of the peptide Different MHC alleles confer different functional properties on the adaptive immune system by specifying molecules that have different peptide binding abilities Location of MHC class I pockets termed B

More information

Immunology for the Rheumatologist

Immunology for the Rheumatologist Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the

More information

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)

Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central

More information

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole

More information

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?

More information

T Cell Activation, Costimulation and Regulation

T Cell Activation, Costimulation and Regulation 1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family

More information

SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE

SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE SOMAPLEX REVERSE PHASE PROTEIN MICROARRAY HUMAN KIDNEY TUMOR & NORMAL TISSUE 45 CLINICAL CASES SERIAL DILUTION MULTIPLE PROTEIN CONCENTRATION QUANTITATIVE ASSAY PRODUCT NUMBER: PM1-001-N SOMAPLEX REVERSE

More information

Review Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease Jerome R Bill and Brian L Kotzin

Review Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease Jerome R Bill and Brian L Kotzin Review Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease Jerome R Bill and Brian L Kotzin Departments of Medicine and Immunology, University of Colorado

More information

LG-APM s for MHC-Peptide Screening

LG-APM s for MHC-Peptide Screening LG-APM s for MHC-Peptide Screening S. Stanley*, I. A. Dodi* #, C.R. Evans*, S. J. Paston #, R.C. Rees*, C.J. Percival $, Glen McHale* and M.I Newton* *School of Biomedical & Natural Sciences, Nottingham

More information

Rapid antigen-specific T cell enrichment (Rapid ARTE)

Rapid antigen-specific T cell enrichment (Rapid ARTE) Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role

More information

The Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions. Edita Karosiene, Ph.D.

The Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions. Edita Karosiene, Ph.D. The Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions Edita Karosiene, Ph.D. edita@liai.org IEDB Workshop October 29, 2015 Outline Introduction MHC-I peptide binding prediction

More information

CONVENTIONAL VACCINE DEVELOPMENT

CONVENTIONAL VACCINE DEVELOPMENT CONVENTIONAL VACCINE DEVELOPMENT PROBLEM Lethal germ Dead mouse LIVE VACCINES Related but harmless germ gives protection against lethal pathogen. Examples are the original pox vaccine and some TB vaccines

More information

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmunity Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmune disease can be caused to primary defects in B cells, T cells and possibly

More information

Antigen Presentation to T lymphocytes

Antigen Presentation to T lymphocytes Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antibodies and T cell receptors

More information

T cell development October 28, Dan Stetson

T cell development October 28, Dan Stetson T cell development October 28, 2016 Dan Stetson stetson@uw.edu 441 Lecture #13 Slide 1 of 29 Three lectures on T cells (Chapters 8, 9) Part 1 (Today): T cell development in the thymus Chapter 8, pages

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

Chemical Biology, Option II Mechanism Based Proteomic Tagging Case History CH1

Chemical Biology, Option II Mechanism Based Proteomic Tagging Case History CH1 Proteome Wide Screening of Serine Protease Activity Proc Natl Acad Sci 1999, 97, 14694; Proteomics 2001, 1, 1067; Proc Natl Acad Sci 2002, 99, 10335; Biochemistry 2001, 40, 4005; J. Am. Chem. Soc., 2005,

More information